Megan Yuen

Clinical Outcomes With Abemaciclib After Prior CDK4/6 Inhibitor Progression in Breast Cancer: A Multicenter Experience

Seth A. Wander, Hyo S. Han, Mark L. Zangardi et al. · Journal of the National Comprehensive Cancer Network · 2021 · 85 citations

Medicine, Oncology, Pharmacology +16

<i>FGFR1</i> Amplification Mediates Endocrine Resistance but Retains TORC Sensitivity in Metastatic Hormone Receptor–Positive (HR+) Breast Cancer

Joshua Z. Drago, Luigi Formisano, Dejan Juric et al. · Clinical Cancer Research · 2019 · 78 citations · Full text

Medicine, Endocrinology, Oncology +17

Comparison of tissue genotyping (TG) vs circulating tumor DNA (ctDNA) for selection of matched therapy and impact on clinical outcomes among patients with metastatic breast cancer (MBC).

Neelima Vidula, Dejan Juric, Andrzej Niemierko et al. · Journal of Clinical Oncology · 2018 · 40 citations

Medicine, Molecular Medicine, Oncology +17

A multicenter analysis of abemaciclib after progression on palbociclib in patients (pts) with hormone receptor-positive (HR+)/HER2- metastatic breast cancer (MBC).

Seth A. Wander, Mark L. Zangardi, Andrzej Niemierko et al. · Journal of Clinical Oncology · 2019 · 36 citations

Medicine, Oncology, Pharmacology +17

Blood-based monitoring identifies acquired and targetable driver HER2 mutations in endocrine-resistant metastatic breast cancer

Arielle J. Medford, Taronish D. Dubash, Dejan Juric et al. · npj Precision Oncology · 2019 · 30 citations · Full text

Medicine, Oncology, Pharmacology +17